Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Primary Care
How do you approach treatment intensification in patients with RA and low disease activity but not in remission, considering the potential risks of increased immunosuppression?
Related Questions
What is your treatment approach for a young female who has an idiopathic small right elbow effusion with synovial thickening that has resulted in limitation in her range of motion?
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
What is your approach to monitoring patients referred for high titer +RF and +CCP but without active symptoms of inflammatory arthritis?
Are you comfortable with using NSAIDs in a patient on methotrexate for inflammatory arthritis?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
When considering a biologic for seropositive RA after failure of methotrexate or triple therapy, do you consider using abatacept as a first line biologic or would prefer choosing TNFi?
During treatment of severe osteoporosis, with PTH analogs (abaloparatide or) would rise in alkaline phosphatase level > 200 (in setting of normal GGT) warrant discontinuation of medication?
What is your approach to methotrexate use (or avoidance) in patients with varying MTHFR mutations?
Would you escalate therapy in a patient with rheumatoid arthritis without synovitis, but a new rheumatoid nodule?
